European journal of radiology · 2025
Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis - A retrospective single-institution study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yuan Gavin, Petre Elena N, Marquis Harry, Kesner Adam, Lundi Steven, Rodriguez Lee, Moskowitz Chaya S, White Charlie, Zhao Ken, Sotirchos Vlasios, Reidy-Lagunes Diane, Raj Nitya, Ziv Etay, Alexander Erica S
Аннотация
PURPOSE: To determine safety and efficacy of Yttrium-90 transarterial radioembolization (TARE) for neuroendocrine liver metastases (NLM).
MATERIALS AND METHODS: Retrospective analysis of 39 patients [17 male; mean age 65.5 years (SD ± 12.25)] who underwent 57 TARE treatments with glass/resin microspheres from 4/2012-12/2022. Primary site included: pancreas (n = 16), small bowel (n = 7), rectum (n = 4), lung (n = 5), NET of unknown origin (n = 4), colon (n = 1), kidney (n = 1), and stomach (n = 1). Overall survival (OS) and time to ascites development were estimated via Kaplan-Meier method. Cox proportional hazards models assessed association between patient characteristics and OS. Local tumor progression (LTP) was analyzed using a competing risks framework with death without local progression treated as the competing risk. Complications were graded via: Common Terminology Criteria for Adverse Events.
RESULTS: Cumulative incidence of LTP was 45 % (95 % CI: 31 %-59 %) at 1-year among all procedures. Ki-67 index was significantly associated with local progression; tumors with a Ki-67 index of more than 20 % had increased risk of recurrence vs those with Ki-67 ≤20 % (HR = 2.82, 95 % CI (1.24, 6.39); p = 0.013). Median OS was 31 months (95 %CI: 20-NR). Patients with tumor burden ≥50 % vs <50 % of liver volume had an increased risk of death, though this was not statistically significant (HR = 2.24, 95 %CI (0.92, 5.44); p = 0.075). Two patients (3.5 %, 95 % CI: 0.4 %, 12.1 %) developed complications within 30 days requiring hospitalization: fatigue, nausea, and pain (grade 1); spinal infarct with motor and sensory losses (grade 3).
CONCLUSION: TARE is safe for NLM. LTP was better in patients with lower Ki-67 index.
MATERIALS AND METHODS: Retrospective analysis of 39 patients [17 male; mean age 65.5 years (SD ± 12.25)] who underwent 57 TARE treatments with glass/resin microspheres from 4/2012-12/2022. Primary site included: pancreas (n = 16), small bowel (n = 7), rectum (n = 4), lung (n = 5), NET of unknown origin (n = 4), colon (n = 1), kidney (n = 1), and stomach (n = 1). Overall survival (OS) and time to ascites development were estimated via Kaplan-Meier method. Cox proportional hazards models assessed association between patient characteristics and OS. Local tumor progression (LTP) was analyzed using a competing risks framework with death without local progression treated as the competing risk. Complications were graded via: Common Terminology Criteria for Adverse Events.
RESULTS: Cumulative incidence of LTP was 45 % (95 % CI: 31 %-59 %) at 1-year among all procedures. Ki-67 index was significantly associated with local progression; tumors with a Ki-67 index of more than 20 % had increased risk of recurrence vs those with Ki-67 ≤20 % (HR = 2.82, 95 % CI (1.24, 6.39); p = 0.013). Median OS was 31 months (95 %CI: 20-NR). Patients with tumor burden ≥50 % vs <50 % of liver volume had an increased risk of death, though this was not statistically significant (HR = 2.24, 95 %CI (0.92, 5.44); p = 0.075). Two patients (3.5 %, 95 % CI: 0.4 %, 12.1 %) developed complications within 30 days requiring hospitalization: fatigue, nausea, and pain (grade 1); spinal infarct with motor and sensory losses (grade 3).
CONCLUSION: TARE is safe for NLM. LTP was better in patients with lower Ki-67 index.